CT 15 2002 8

2300 - 1 BOX Seh

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date: <u>Volober 11 2002</u>

(Signature of person mailing paper)

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

) Group Art Unit: 1633	
) Attorney Docket No. 24	10.1PCD
) Examiner: unassigned	
)	
) Customer No. 25000	
)	
)	
)	
)	
)	
	) Attorney Docket No. 24 ) Examiner: unassigned )

## RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Dear Sir:

This is in response to the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" with a response date of October 21, 2002. Applicants respectfully submit the following information (which is attached to this transmittal):

- 1) A substitute computer readable form as required by 37 C.F.R. 1.825(d);
- 2) A paper copy of the Sequence Listing (which was originally submitted on July 19, 2002;

- Accordance "Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1.821 – 1.825", which was originally filed on July 19, 2002; and
- A copy of the "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures".

Applicants believe that no extension of term or other fees are required. If, however, any extension or fee is required, please charge Account No. 07-1250.

Respectfully submitted,

Mark L. Bosse

Registration No. 35,071

Date:

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404

Facsimile:

*Telephone:* (650) 522-5569 (650) 522-5575

email:

mark\_bosse@gilead.com

OCT 1 5 2002

TENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENT UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023 WWW.usplo.go.



Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual - ePAVE)

## 2. Mailed to:


U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Mailed by Federal Express, United Parcel Service or other delivery service to:

 U. S. Patent and Trademark Office
 2011 South Clark Place
 Customer Window, Box Sequence
 Crystal Plaza Two, Lobby, Room 1B03
 Arlington, Virginia 22202

 Hand Carried directly to the Customer Window at: 2011 South Clark Place Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202

Rev. 12/27/2001





COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/086.816

02/28/2002

Tomas Cihlar

240.1PCD

25000 GILEAD SCIENCES INC 333 LAKESIDE DR FOSTER CITY, CA 94404 CONFIRMATION NO. 3270
FORMALITIES LETTER
\*OC000000008659023\*

Date Mailed: 08/21/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE